P/E ratio for TherapeuticsMD (TXMD)
P/E ratio as of April 2024 (TTM): 0.3888
According to TherapeuticsMD's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0.388773. At the end of 2022 the company had a P/E ratio of 0.4454.
P/E ratio history for TherapeuticsMD from 2007 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | 0.4454 | -153.7% |
| 2021 | -0.8295 | -54.07% |
| 2020 | -1.81 | -47.01% |
| 2019 | -3.41 | -47.22% |
| 2018 | -6.46 | -59.37% |
| 2017 | -15.9 | 29.47% |
| 2016 | -12.3 | -40.81% |
| 2015 | -20.7 | 63.12% |
| 2014 | -12.7 | -43.87% |
| 2013 | -22.7 | 184.98% |
| 2012 | -7.95 | 3140.7% |
| 2011 | -0.2453 | 45.21% |
| 2010 | -0.1689 | -98.78% |
| 2009 | -13.8 | 286.8% |
| 2008 | -3.57 | 27.38% |
| 2007 | -2.80 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | 13.7 | 3,411.17% | 🇺🇸 USA |
 AbbVie ABBV | 43.4 | 11,054.92% | 🇺🇸 USA |
 Agile Therapeutics
AGRX | -0.0101 | -102.60% | 🇺🇸 USA |
 Royalty Pharma RPRX | 50.9 | 12,994.81% | 🇬🇧 UK |
 Lannett Company LCI | -0.0271 | -106.97% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.